Folate and macrophage folate receptor-β in idiopathic pulmonary fibrosis disease: the potential therapeutic target?

Biomed Pharmacother. 2020 Nov:131:110711. doi: 10.1016/j.biopha.2020.110711. Epub 2020 Sep 9.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, fatal disease with high mortality and poor prognosis. It is characterized by a gradual decline in lung function, and there are currently no effective therapeutic methods. Folate is a water-soluble B vitamin that plays an important role in one-carbon transfer reactions, nucleic acid biosynthesis and methylation reactions. Studies have shown that folate may participate in the pathogenesis of IPF through ways of DNA repair, methylation, and reactive oxygen species. Macrophage activation is an important early cellular event in IPF and the inflammatory response that they trigger is a significant feature of IPF. Folate receptor-β (FR-β) is a cell surface glycosylphosphatidylinositol-anchored glycoprotein that can mediate the unidirectional transport of folate into cells. And it has been found in previous studies that FR-β is usually overexpressed on activated macrophages, but the expression on resting macrophages was undetectable. Therefore, targeting FR-β may have potential value for the early diagnosis and therapy of IPF. Our goal is to highlight the biological role of folate and FR-β in IPF, and we hope to provide helpful insight for clinical treatment strategies.

Keywords: Folate; Folate receptor; IPF; Macrophage.

Publication types

  • Review

MeSH terms

  • Cell Polarity
  • Folate Receptor 2 / antagonists & inhibitors
  • Folate Receptor 2 / chemistry
  • Folate Receptor 2 / physiology*
  • Folic Acid / physiology*
  • Humans
  • Idiopathic Pulmonary Fibrosis / diagnosis
  • Idiopathic Pulmonary Fibrosis / drug therapy
  • Idiopathic Pulmonary Fibrosis / etiology*
  • Macrophages / physiology*
  • Toll-Like Receptor 4 / physiology

Substances

  • Folate Receptor 2
  • Toll-Like Receptor 4
  • Folic Acid